Precision Prevention Strategy to Increase Uptake and Engagement in Lung Cancer Screening and Smoking Cessation Treatment
This trial tests the effects of two versions of RiskProfile, a clinically-informed and a genetically-informed version of a patient-specific risk feedback tool, in comparison to usual care, on lung cancer screening and tobacco treatment. The trial assesses the multilevel effects of these precision risk feedback tools on the likelihood of clinicians to order lung cancer screening and tobacco treatment and of their patients to utilize these cancer prevention interventions.
Checked against the public recordLast updated Aug 6, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Washington University School of Medicine
- Interventions being studied
- Behavioral: Usual Care; Behavioral: RiskProfile-Clin; Behavioral: RiskProfile-Gen
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: CLINICIANS: \- Primary care clinician with active caseload in participating clinics PATIENTS: * Patient of participating primary care clinician * Lung cancer screening naïve * Between 50 to 80 years of age, inclusive * Current or former smokers * Pack years ≥ 20 * English-speaking Exclusion Criteria: PATIENTS: * Lung cancer diagnosis * Current order placed for lung cancer screening
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Washington University School of MedicineSt Louis, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 6, 2026. Always confirm current availability with the study team.